Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Preparing compound containing saccharide radical
Reexamination Certificate
2011-05-31
2011-05-31
Benzion, Gary (Department: 1637)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Preparing compound containing saccharide radical
C435S006120
Reexamination Certificate
active
07951563
ABSTRACT:
Aspects of the invention provide methods, nucleic acids and kits for detecting, or for detecting and distinguishing between or among liver cell proliferative disorders or for detecting, or for detecting and distinguishing between or among colorectal cell proliferative disorders. Particular aspects disclose and provide genomic sequences the methylation patterns of which have substantial utility for the improved detection of and differentiation between said class of disorders, thereby enabling the improved diagnosis and treatment of patients.
REFERENCES:
patent: 5565552 (1996-10-01), Magda et al.
patent: 5567810 (1996-10-01), Weis et al.
patent: 5574142 (1996-11-01), Meyer, Jr. et al.
patent: 5585481 (1996-12-01), Arnold, Jr. et al.
patent: 5587371 (1996-12-01), Sessler et al.
patent: 5597696 (1997-01-01), Linn et al.
patent: 5786146 (1998-07-01), Herman et al.
patent: 5958773 (1999-09-01), Monia et al.
patent: 6251594 (2001-06-01), Gonzalgo et al.
patent: 6265171 (2001-07-01), Herman et al.
patent: 6331393 (2001-12-01), Laird et al.
patent: 6783933 (2004-08-01), Issa
patent: 7112404 (2006-09-01), Laird
patent: 2003/0013091 (2003-01-01), Dimitrov
patent: WO 95/00669 (1995-01-01), None
patent: WO 95/15373 (1995-06-01), None
patent: WO 97/46705 (1997-12-01), None
patent: WO 99/28498 (1999-06-01), None
patent: WO 99/31233 (1999-06-01), None
patent: WO 00/26401 (2000-05-01), None
patent: WO 03/042661 (2003-05-01), None
patent: WO 04/000463 (2003-12-01), None
patent: WO 2004/074441 (2004-09-01), None
patent: WO 2005/001141 (2005-01-01), None
patent: WO 2005/038051 (2005-04-01), None
Schuebel et al., PLoS Genetics, vol. 3, iss. 9, pp. e157; 1709-1723, Sep. 2007.
U.S. Appl. No. 60/672,242, filed Apr. 15, 2005, Lofton-Day et al.
U.S. Appl. No. 60/676,997, filed May 2, 2005, Lofton-Day et al.
U.S. Appl. No. 60/697,521, filed Jul. 8, 2005, Lesche et al.
U.S. Appl. No. 60/704,860, filed Aug. 1, 2005, Lesche et al.
U.S. Appl. No. 60/709,318, filed Aug. 17, 2005, Lesche et al.
U.S. Appl. No. 60/723,602, filed Oct. 4, 2005, Lesche et al.
U.S. Appl. No. 60/787,402, filed Mar. 30, 2006, Lesche et al.
Belyavsky et al., “PCR-based cDNA library construction: general cDNA libraries at the level of a few cells,” Nucleic Acids Research, 1989, pp. 2919-2932, vol. 17.
Beysen et al., “The Human FOXL2 Mutation Database,” Human Mutation, 2004, pp. 189-193, vol. 24.
Bloemental et al., “Activated vitronectin as a target for anticancer therapy with human antibodies,” Cancer Immunology, Immunotherapy, 2004, pp. 799-808, vol. 53.
Bowtell, “Options available—from start to finish—for obtaining expression data by microarray,” Nature Genetics Supplement, Jan. 1999, pp. 25-32, vol. 21.
Burrows et al., “Altered expression of the septin gene, SEPT9, in ovarian neoplasia,” Journal of Pathology, 2003, pp. 581-588, vol. 201.
Cocquet et al., “Evolution and expression of FOXL2,” Journal of Medical Genetics, 2002, pp. 916-922, vol. 39.
Cosgaya et al., “The Neurotrophin Receptor p75NTRas a Positive Modulator of Myelination,” Science, 2002, pp. 1245-1248, vol. 298.
Database EMBL, “Homo sapienschromosome 17, clone RP11-936I5,” Feb. 18, 2002, Database Accession No. EM—HUM:AC111182.
De Baere et al., “FOXL2 and BPES: Mutational Hotspots, Phenotypic Variability, and Revision of the Genotype-Phenotype Correlation,” American Journal of Human Genetics, 2003, pp. 478-487, vol. 72.
Dobrowsky et al., “Activation of the Sphingomyelin Cycle Through the Low-Affinity Neurotrophin Receptor,” Science, 1994, pp. 1596-1599, vol. 265.
Eads et al., “CpG Island Hypermethylation in Human Colorectal Tumors Is Not Associated with DNA Methyltransferase Overexpression,” Cancer Research, May 15, 1999, pp. 2302-2306, vol. 59.
Feil et al., “Methylation analysis on individual chromosomes: improved protocol for bisulphite genomic sequencing,” Nucleic Acids Research, 1994, pp. 695-696, vol. 22.
Frommer et al., “A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands,” PNAS, Mar. 1992, pp. 1827-1831, vol. 89.
Galfre et al., “Preparation of Monoclonal Antibodies: Strategies and Procedures,” Methods in Enzymology, 1981, pp. 3-46, vol. 73.
Gonzalgo et al., “Identification and Characterization of Differentially Methylated Regions of Genomic DNA by Methylation-sensitve Arbitrarily Primed PCR,” Cancer Research, Feb. 15, 1997, pp. 594-599, vol. 57.
Gonzalgo et al., Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE), Nucleic Acids Research, 1997, pp. 2529-2531, vol. 25, No. 12.
Grigg et al., “Sequencing 5-Methylcytosine Residues in Genomic DNA,” BioEssays, Jun. 1994, pp. 431-436, vol. 16, No. 6.
Gut et al, “DNA and Matrix Assisted Laser Desorption Ionization Mass Spectrometry,” Molecular Biology: Current Innovations and Future Trends, 1995, pp. 147-157, Horizon Scientific Press, Wymondham, United Kingdom.
Gut et al., “A procedure for selection DNA alkylation and detection by mass spectrometry,” Nucleic Acids Research, 1995, pp. 1367-1373, vol. 23.
Haier et al., “Inhibition of tumor progression and neoangiogenesis using cyclic RGD-peptides in a chemically induced colon carcinoma in rats,” Clinical & Experimental Metastasis, 2002, pp. 665-672, vol. 19.
Heid et al., “Real Time Quantitative PCR,” Genome Research, 1996, pp. 986-994, vol. 6.
Herman et al., “Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands,” Sep. 1996, pp. 9821-9826, vol. 93.
Kalikin et al., “Genomic and Expression Analyses of Alternatively Spliced Transcripts of the MLL Septin-like Fusion Gene (MSF) That Map to a 17q25 Region of Loss in Breast and Ovarian Tumors,” Genomics, 2000, pp. 165-172, vol. 63.
Karas et al., “Laser Desorption Ionization of Proteins with Molecular Masses Exceeding 10 000 Daltons,” Analytical Chemistry, Oct. 15, 1988, pp. 2299-2301, vol. 60.
Koehler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, Aug. 7, 1975, pp. 495-496, vol. 256.
Krug et al., “First-Strand cDNA Synthesis Primed with Oligo(dT),” Methods in Enzymology, 1987, pp. 316-325, vol. 152.
Liang et al., “The Gene for a Novel Transmembrane Protein Containing Epidermal Growth Factor and Follistatin Domains Is Frequently Hypermethylated in Human Tumor Cells,” Cancer Research, 2000, pp. 4907-4912, vol. 60.
Lipshutz et al., “High density synthetic oligonucleotide arrays,” Nature Genetics Supplement, Jan. 1999, pp. 20-24, vol. 21.
Martin et al., “Genomic sequencing indicates a correlation between DNA hypomethylation in the 5′ region of the pS2 gene and its expression in human breast cancer cell lines,” Gene, 1995, pp. 261-264, vol. 157.
McIlhatton et al., “Genomic organization, complex splicing pattern and expression of a human septin gene on chromosome 17q25.3,” Oncogene, 2001, pp. 5930-5939, vol. 20.
Mink et al., “A Novel Human Gene (SARM) at Chromosome 17q11 Encodes a Protein with a SAM Motif and Structural Similarity to Armadillo/β-Catenin That Is Conserved in Mouse,Drosophila, andCaenorhabditis elegans,” Genomics, 2001, pp. 234-244, vol. 74.
Olek et al., “A modified and improved method for bisulphite based cytosine methylation analysis,” Nucleic Acids Research, 1996, pp. 5064-5066, vol. 24.
Olek et al., “The pre-implantation ontogeny of the H19 methylation imprint,” Nature Genetics, Nov. 1997, pp. 275-276, vol. 17.
Osaka et al., “MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23:q25),” PNAS, May 1999, pp. 6428-6433, vol. 96.
Rein et a
Distler Juergen
Hildmann Thomas
Lesche Ralf
Lofton-Day Catherine
Model Fabian
Benzion Gary
DLA Piper (LLP) US
Epigenomics AG
Wilder Cynthia B
LandOfFree
Methods and nucleic acids for analysis of cellular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and nucleic acids for analysis of cellular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and nucleic acids for analysis of cellular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2678801